Geode Capital Management LLC Sells 37,043 Shares of Bioverativ Inc (BIVV)

Geode Capital Management LLC decreased its position in Bioverativ Inc (NASDAQ:BIVV) by 3.7% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 969,103 shares of the biotechnology company’s stock after selling 37,043 shares during the period. Geode Capital Management LLC owned 0.90% of Bioverativ worth $52,254,000 as of its most recent SEC filing.

Several other institutional investors have also recently bought and sold shares of the company. Public Employees Retirement Association of Colorado increased its stake in Bioverativ by 3.3% in the fourth quarter. Public Employees Retirement Association of Colorado now owns 21,522 shares of the biotechnology company’s stock valued at $1,160,000 after purchasing an additional 690 shares during the period. Hendershot Investments Inc. boosted its holdings in shares of Bioverativ by 4.8% in the fourth quarter. Hendershot Investments Inc. now owns 17,662 shares of the biotechnology company’s stock valued at $952,000 after acquiring an additional 807 shares in the last quarter. Raymond James Trust N.A. boosted its holdings in shares of Bioverativ by 16.4% in the fourth quarter. Raymond James Trust N.A. now owns 6,072 shares of the biotechnology company’s stock valued at $328,000 after acquiring an additional 855 shares in the last quarter. Amalgamated Bank boosted its holdings in shares of Bioverativ by 5.6% in the fourth quarter. Amalgamated Bank now owns 22,800 shares of the biotechnology company’s stock valued at $1,229,000 after acquiring an additional 1,205 shares in the last quarter. Finally, Meeder Asset Management Inc. boosted its holdings in shares of Bioverativ by 10.7% in the fourth quarter. Meeder Asset Management Inc. now owns 17,045 shares of the biotechnology company’s stock valued at $919,000 after acquiring an additional 1,653 shares in the last quarter. 97.18% of the stock is owned by institutional investors and hedge funds.

How to Become a New Pot Stock Millionaire

BIVV has been the topic of a number of research analyst reports. Zacks Investment Research raised shares of Bioverativ from a “hold” rating to a “buy” rating and set a $62.00 price objective on the stock in a report on Monday, January 8th. William Blair reissued a “hold” rating on shares of Bioverativ in a research report on Thursday, March 8th. Royal Bank of Canada upped their price target on shares of Bioverativ to $68.00 and gave the stock a “market perform” rating in a research report on Thursday, January 18th. Jefferies Group upped their price target on shares of Bioverativ to $79.00 and gave the stock a “buy” rating in a research report on Thursday, January 18th. Finally, Raymond James Financial downgraded shares of Bioverativ from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, January 23rd. Twelve equities research analysts have rated the stock with a hold rating and two have issued a buy rating to the company’s stock. The company presently has an average rating of “Hold” and a consensus target price of $64.70.

Shares of BIVV remained flat at $$104.98 during midday trading on Friday. Bioverativ Inc has a 12-month low of $48.14 and a 12-month high of $105.01.

Bioverativ (NASDAQ:BIVV) last posted its quarterly earnings results on Tuesday, February 13th. The biotechnology company reported $0.76 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.75 by $0.01. The business had revenue of $328.70 million during the quarter, compared to analyst estimates of $325.89 million. Bioverativ had a net margin of 30.43% and a return on equity of 40.99%. equities analysts predict that Bioverativ Inc will post 3.82 EPS for the current year.

WARNING: “Geode Capital Management LLC Sells 37,043 Shares of Bioverativ Inc (BIVV)” was first reported by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are reading this article on another site, it was copied illegally and republished in violation of U.S. and international copyright laws. The correct version of this article can be viewed at https://www.dispatchtribunal.com/2018/04/08/geode-capital-management-llc-sells-37043-shares-of-bioverativ-inc-bivv.html.

Bioverativ Profile

Bioverativ Inc (Bioverativ) is a biotechnology company. The Company is focused on the discovery, research, development and commercialization of therapies for the treatment of hemophilia and other blood disorders. It markets approximately two products, including ELOCTATE [Antihemophilic Factor (Recombinant), Fc Fusion Protein], and ALPROLIX [Coagulation Factor IX (Recombinant), Fc Fusion Protein], extended half-life clotting-factor therapies for the treatment of hemophilia A and hemophilia B, respectively.

Institutional Ownership by Quarter for Bioverativ (NASDAQ:BIVV)

Receive News & Ratings for Bioverativ Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bioverativ and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply